Different Metabolic Effects of Statins

This study has been completed.

Sponsor:

Information provided by:

Gachon University Gil Medical Center

ClinicalTrials.gov Identifier:

NCT01011127

First received: November 10, 2009

Last updated: October 4, 2010

Last verified: October 2010

History of Changes

Purpose

The investigators hypothesize that pravastatin and rosuvastatin may have different metabolic effects in hypercholesterolemic patients.

Condition	Intervention
Hypercholesterolemia	Drug: pravastatin, rosuvastatin

Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cholesterol Diabetes Medicines Statins

Drug Information available for: Pravastatin Pravastatin sodium Rosuvastatin calcium Rosuvastatin

U.S. FDA Resources

Further study details as provided by Gachon University Gil Medical Center:

Study Start Date:	December 2009
Study Completion Date:	August 2010
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts	Assigned Interventions
pravastatin	Drug: pravastatin, rosuvastatin
rosuvastatin	Drug: pravastatin, rosuvastatin

Eligibility

Ages Eligible for Study:	25 Years to 75 Years
Genders Eligible for Study:	Both
Sampling Method:	Probability Sample

Study Population

Hypercholesterolemia

Criteria

Inclusion Criteria:

Low-density lipoprotein cholesterol levels>130

Exclusion Criteria:

Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01011127

Locations

Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405-760

Sponsors and Collaborators

Gachon University Gil Medical Center

More Information

Publications:

Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13.

ClinicalTrials.gov Identifier:	NCT01011127 History of Changes
Other Study ID Numbers:	GMC-200914
Study First Received:	November 10, 2009
Last Updated:	October 4, 2010
Health Authority:	South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:

Statins
Insulin resistance

Additional relevant MeSH terms:

Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pravastatin
Rosuvastatin
Anticholesteremic Agents

Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 23, 2013

To Top